Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Regulus Therapeutics Inc. [1][2] - The tender offer includes $7.00 in cash per share and one contingent value right (CVR) per share, which represents the right to receive an additional $7.00 upon achieving a regulatory milestone [1][2]. - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated April 29, 2025 [2]. Tender Offer Details - The offer will expire one minute past 11:59 p.m. New York City Time on June 24, 2025, unless extended or terminated earlier [2]. - The completion of the transaction requires validly tendered shares that, along with shares owned by Novartis and its subsidiaries, represent at least one more than 50% of the total outstanding shares [2]. Additional Information - Novartis and its subsidiary filed a tender offer statement with the U.S. Securities and Exchange Commission (SEC), and Regulus filed a solicitation/recommendation statement regarding the tender offer [3]. - Investors are encouraged to read the tender offer materials and the solicitation/recommendation statement for important information before making decisions [4].